Author(s)

Xinyi Cui ¹, Hai Lin ²

Affiliation(s)

¹ Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
² The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xi'an, Shaanxi, China

Corresponding Author

Hai Lin

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disease that has seriously affected public health. Although the scientists have studied AD deeply and explored several therapeutic strategies, there is still no complete cure. Therefore, early diagnosis and treatment is the key to addressing AD problems. This review includes currently accepted pathological hypotheses for Alzheimer's disease (AD), such as β -amyloid (A β) deposition, tau phosphorylation, cholinergic hypothesis, and inflammatory response. The early diagnosis of AD, including neuropsychological assessment, biomarker detection, and imaging techniques, highlights a new immunotherapy drug called lecanemab and its clinical trial results. It can reduce Aβ levels, improve cognitive function, and delay the progression of the disease. But problems remain regarding side effects, costs, and patient compliance. At present, AD treatment is facing challenges, which needs to explore new therapeutic targets and drugs, and optimize therapeutic strategies. At the same time, strengthening the research and application of early diagnosis technology, improving the awareness of AD among patients and their families, is help to improve the quality of life of patients and reduce the social and family burden. Countries need to invest more to promote the development of AD research and clinical practice.

KEYWORDS

Alzheimer's Disease, AD, Lecanemab, Early Diagnosis, Treatment, Immunotherapy

CITE THIS PAPER

Xinyi Cui, Hai Lin, Recent Advances on Early Diagnosis and Immunotherapy Drug for Alzheimer's Disease. MEDS Basic Medicine (2024) Vol. 2: 131-138. DOI: http://dx.doi.org/10.23977/medbm.2024.020117.

REFERENCES

[1] Cho Y, Bae H G, Okun E, Arumugam T V, Jo D G. Physiology and pharmacology of amyloid precursor protein. Pharmacol Ther. 2022 Jul; 235:108122. doi: 10.1016/j.pharmthera.2022.108122.
[2] Ma C, Hong F, Yang S. Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules. 2022 Feb 11; 27(4):1210. doi: 10.3390/molecules27041210. PMID: 35209007; PMCID: PMC8876037.
[3] Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019 Jul 19; 14:5541-5554. doi: 10.2147/IJN.S200490. PMID: 31410002; PMCID: PMC6650620.
[4] Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020 Dec 8; 25(24):5789. doi: 10.3390/molecules25245789. PMID: 33302541; PMCID: PMC7764106.
[5] Chen ZR, Huang JB, Yang SL, Hong FF. Role of Cholinergic Signaling in Alzheimer's Disease. Molecules. 2022 Mar 10; 27(6):1816. doi: 10.3390/molecules27061816. PMID: 35335180; PMCID: PMC8949236.
[6] Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, Malaplate C, Yen FT, Arab-Tehrany E. Alzheimer's Disease: Treatment Strategies and Their Limitations. Int J Mol Sci. 2022 Nov 12; 23(22):13954. doi: 10.3390/ijms232213954. PMID: 36430432; PMCID: PMC9697769.
[7] Self W K, Holtzman D M. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med. 2023 Sep; 29(9):2187-2199. doi: 10.1038/s41591-023-02505-2. Epub 2023 Sep 4. PMID: 37667136.
[8] Wang Q, Duan L, Li X, Wang Y, Guo W, Guan F, Ma S. Glucose Metabolism, Neural Cell Senescence and Alzheimer's Disease. Int J Mol Sci. 2022 Apr 14; 23(8):4351. doi: 10.3390/ijms23084351. PMID: 35457168; PMCID: PMC9030802.
[9] Silva M V F, Loures C M G, Alves L C V, De Souza L C, Borges K B G, Carvalho M D G. Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci. 2019 May 9; 26(1):33. doi: 10.1186/s12929-019-0524-y. PMID: 31072403; PMCID: PMC6507104.
[10] Cummings J L, Tong G, Ballard C. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis. 2019; 67(3):779-794. doi: 10.3233/JAD-180766. PMID: 30689575; PMCID: PMC6398562.
[11] Marucci G, Buccioni M, Ben D D, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021 Jun 1; 190: 108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. PMID: 33035532.
[12] McDade E, Cummings J L, Dhadda S, Swanson C J, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer L D, Bateman R J. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022 Dec 21; 14(1):191. doi: 10.1186/s13195-022-01124-2. PMID: 36544184; PMCID: PMC9768996.
[13] Cohen S, van Dyck C H, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L D. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2023; 10(4):771-777. doi: 10.14283/jpad.2023.123. PMID: 37874099.
[14] Swanson C J, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry D A, Berry S, Gordon R, Kramer L D, Cummings J L. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021 Apr 17; 13(1):80. doi: 10.1186/s13195-021-00813-8. Erratum in: Alzheimers Res Ther. 2022 May 21; 14(1):70. PMID: 33865446; PMCID: PMC8053280.
[15] Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci. 2023 May 5; 15: 1169499. doi: 10.3389/fnagi.2023. 1169499. PMID: 37213538; PMCID: PMC10196238.

Sponsors, Associates, and Links

---

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine